© 1999 by Oxford University Press and the Maryland Psychiatric Research Center (MPRC)
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Bixler Professor of Psychiatry and Pharmacology and Director of the Division of Psychopharmacology, Vanderbilt University Medical Center Nashville, TN
Assistant Professor of Psychiatry, Mt. Sinai School of Medicine New York, NY
Reprint requests should be sent to Dr. H.Y. Meltzer, Dept. of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37215
Cognitive function is markedly impaired in most patients with schizophrenia. Antecedents of this impairment are evident in childhood. The cognitive disability is nearly fully developed at the first episode of psychosis in most patients. The contribution of cognitive impairment to outcome in schizophrenia, especially work function, has been established. Preliminary results indicate that cognitive function, along with disorganization symptoms, discriminate schizophrenia patients who are able to work full-time from those who are not. Typical neuroleptic drugs lack the ability to improve the various domains of cognitive function impaired in schizophrenia. Atypical antipsychotic drugs pharmacologically related to clozapine—quetiapine, olanzapine, risperidone, sertindole, and ziprasidone—share the ability to produce fewer extrapyramidal symptoms than typical neuroleptic drugs and more potent antagonism of serotonin2a relative to dopamine2 receptors. However, they have a number of different clinical effects. We have identified all the studies of clozapine, olanzapine, and risperidone that provide data on their effects on cognition in schizophrenia. Data for each drug are reviewed separately in order to identify differences among them in their effects on cognition. Twelve studies that report cognitive effects of clozapine are reviewed. These studies provide (1) strong evidence that clozapine improves attention and verbal fluency and (2) moderate evidence that clozapine improves some types of executive function. However, results of the effects of clozapine on working memory and secondary verbal and spatial memory were inconclusive. Risperidone has relatively consistent positive effects on working memory, executive functioning, and attention, whereas improvement in verbal learning and memory was inconsistent. Preliminary evidence presented here suggests that olanzapine improves verbal learning and memory, verbal fluency, and executive function, but not attention, working memory, or visual learning and memory. Thus, atypical antipsychotic drugs as a group appear to be superior to typical neuroleptics with regard to cognitive function. However, available data suggest that these drugs produce significant differences in specific cognitive functions. These differences may be valuable adjunctive guides for their use in clinical practice if cognitive improvements reach clinical significance. The effects of the atypical antipsychotic drugs on cholinergic and 5-HT2a-mediated neurotransmission as the possible basis for their ability to improve cognition are discussed. It is suggested that the development of drugs for schizophrenia should focus on improving the key cognitive deficits in schizophrenia: executive function, verbal fluency, working memory, verbal and visual learning and memory, and attention.
Keywords: Cognition / clozapine / neuroleptics / olanzapine / risperidone
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Bubenikova-Valesova, A. Stuchlik, J. Svoboda, J. Bures, and K. Vales Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task PNAS, January 22, 2008; 105(3): 1061 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Silverstein, W. D. Spaulding, A. A. Menditto, A. Savitz, R. P. Liberman, S. Berten, and H. Starobin Attention Shaping: a Reward-Based Learning Method to Enhance Skills Training Outcomes in Schizophrenia Schizophr Bull, January 22, 2008; (2008) sbm150v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Stone and L. J. Seidman Toward a Model of Memory Enhancement in Schizophrenia: Glucose Administration and Hippocampal Function Schizophr Bull, January 1, 2008; 34(1): 93 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Brooks and J. C. Hoblyn Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults J Geriatr Psychiatry Neurol, December 1, 2007; 20(4): 199 - 214. [Abstract] [PDF]
|
|
|
|
|
|
S. Morein-Zamir, D. C. Turner, and B. J. Sahakian A Review of the Effects of Modafinil on Cognition in Schizophrenia Schizophr Bull, November 1, 2007; 33(6): 1298 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Gardell, K. E. Vanover, L. Pounds, R. W. Johnson, R. Barido, G. T. Anderson, I. Veinbergs, A. Dyssegaard, P. Brunmark, A. Tabatabaei, et al. ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 862 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Shaffer, M. Gunduz, R. J. Scialis, and A. F. Fang Metabolism and Disposition of a Selective {alpha}7 Nicotinic Acetylcholine Receptor Agonist in Humans Drug Metab. Dispos., July 1, 2007; 35(7): 1188 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Erickson, J. R. Ciccone, S. B. Schwarzkopf, J. S. Lamberti, and M. J. Vitacco Legal Fallacies of Antipsychotic Drugs J Am Acad Psychiatry Law, June 1, 2007; 35(2): 235 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. E. Keefe, R. M. Bilder, S. M. Davis, P. D. Harvey, B. W. Palmer, J. M. Gold, H. Y. Meltzer, M. F. Green, G. Capuano, T. S. Stroup, et al. Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial Arch Gen Psychiatry, June 1, 2007; 64(6): 633 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Reilly, M. S. H. Harris, M. S. Keshavan, and J. A. Sweeney Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry, November 1, 2006; 63(11): 1189 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Matza, R. Buchanan, S. Purdon, J. Brewster-Jordan, Y. Zhao, and D. A. Revicki Measuring Changes in Functional Status Among Patients With Schizophrenia: The Link With Cognitive Impairment Schizophr Bull, October 1, 2006; 32(4): 666 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Thornton, J. X. Van Snellenberg, A. A. Sepehry, and W. G. Honer The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review J Psychopharmacol, May 1, 2006; 20(3): 335 - 346. [Abstract] [PDF]
|
|
|
|
 |
|
 M. S. KESHAVAN, G. BERGER, R. B. ZIPURSKY, S. J. WOOD, and C. PANTELIS Neurobiology of early psychosis The British Journal of Psychiatry, August 1, 2005; 187(48): s8 - s18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Nasrallah, S. D. Targum, R. Tandon, J. S. McCombs, and R. Ross Defining and Measuring Clinical Effectiveness in the Treatment of Schizophrenia Psychiatr Serv, March 1, 2005; 56(3): 273 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Lafayette, W. G. Frankle, A. Pollock, K. Dyer, and D. C. Goff Clinical Characteristics, Cognitive Functioning, and Criminal Histories of Outpatients With Schizophrenia Psychiatr Serv, December 1, 2003; 54(12): 1635 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Sur, P. J. Mallorga, M. Wittmann, M. A. Jacobson, D. Pascarella, J. B. Williams, P. E. Brandish, D. J. Pettibone, E. M. Scolnick, and P. J. Conn N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity PNAS, November 11, 2003; 100(23): 13674 - 13679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Velligan, F. Lam, L. Ereshefsky, and A. L. Miller Psychopharmacology: Perspectives on Medication Adherence and Atypical Antipsychotic Medications Psychiatr Serv, May 1, 2003; 54(5): 665 - 667. [Abstract] [Full Text] [PDF]
|
|